Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 |
| Operating Profit | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | -0 | 27 | 1 | 21 |
| OPM % | 21% | 51% | 41% | 25% | 12% | 37% | 55% | 24% | -7% | 69% | 11% | 90% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 |
| Tax % | -0% | 1% | 24% | 41% | 39% | 23% | 29% | 26% | -1,090% | 24% | 568% | 26% |
| Net Profit | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 15 |
| EPS in Rs | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 75 |
| Expenses | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 26 |
| Operating Profit | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 49 |
| OPM % | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 51% | 65% |
| Other Income | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 48 |
| Tax % | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | 23% | |
| Net Profit | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 36 |
| EPS in Rs | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 | 0.50 | 0.81 |
| Dividend Payout % | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 5% | 2% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 28% | 38% | -1% | 115% | ||
| Compounded Profit Growth | 53% | 175% | 71% | 256% | ||
| Stock Price CAGR | 72% | 175% | 149% | 72% | ||
| Return on Equity | 20% | 26% | 28% | 29% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 |
| Reserves | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 |
| Borrowings | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 |
| Other Liabilities | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 |
| Total Liabilities | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Fixed Assets | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 |
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Cash from Investing Activity | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Cash from Financing Activity | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -1 | 2 | -1 | -4 | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/OP | 812% | 237% | 7% | 63% | 25% | 81% | 38% | 292% | 64% | -24% | 92% | 17% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 403 | 352 |
| ROCE % | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 22% | 37% |
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.74% |
| No. of Shareholders | 10,963 | 12,974 | 14,989 | 16,321 | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 | 28,384 |
Fundamentals
Market Cap₹ 2,659 Cr.
Current Price₹ 60.3
Stock P/E73.8
Book Value₹ 2.05
ROCE37.0 %
ROE28.9 %
Dividend Yield0.02 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)115%
Compounded Profit Growth (TTM)256%
Standalone figures.
Valuation
Market capRs 2,706 Cr
Enterprise valueRs 2,705 Cr
P/E (TTM)75.09x
Price to book30.12x
Price to sales36.16x
EV / EBITDA51.39x
EV / EBIT55.31x
EV / sales36.15x
Price to cash flow859.08x
Earnings yield1.33%
Dividend yield0.02%
P/E, 3-year average53.54x
P/B, 3-year average10.06x
P/E, 5-year average32.19x
P/B, 5-year average6.04x
Profitability
Operating margin (excl. other income)50.77%
Operating margin (incl. other income)58.84%
EBITDA margin70.35%
Pre-tax margin63.68%
Net profit margin48.16%
Net margin, latest quarter63.90%
ROE28.88%
ROCE36.98%
ROA21.60%
ROE, 3-year average29.83%
ROCE, 3-year average34.34%
ROA, 3-year average19.17%
ROE, 5-year average23.08%
ROCE, 5-year average25.53%
ROA, 5-year average13.53%
ROIC (approx.)42.15%
Tax rate23.35%
Other income / net worth5.10%
Growth
Sales growth (latest year)74.01%
Profit growth (latest year)130.17%
Sales CAGR, 3 years-1.22%
Sales CAGR, 5 years38.37%
Profit CAGR, 3 years71.00%
Profit CAGR, 5 years158.78%
Sales growth QoQ273.33%
Sales growth YoY (latest quarter)336.36%
Profit growth YoY (latest quarter)1359.22%
Per share
EPS (TTM)Rs 0.82
EPS (latest year)Rs 0.50
EPS (latest quarter)Rs 0.34
EPS, 3-year averageRs 5.87
EPS, 5-year averageRs 5.29
Book value per shareRs 2.05
Sales per shareRs 1.71
Cash flow per shareRs 0.07
Free cash flow per shareRs -0.30
Dividend per share (latest year)Rs 0.01
Dividend per share, 3-year averageRs 0.34
Dividend per share, 5-year averageRs 0.34
Dividends
Dividend payout2.00%
Dividend payout, 3-year average4.17%
Dividend payout, 5-year average5.54%
Efficiency
Asset turnover0.48x
Fixed asset turnover2.61x
Inventory turnover1.15x
Inventory days316 days
Debtor days148 days
Debtors turnover2.47x
Creditor days232 days
Cash conversion cycle236 days
Working capital days352 days
Leverage
Total debtRs 5 Cr
Cash and bankRs 6 Cr
Net debtRs -1 Cr
Debt to equity0.06x
Net debt / EBITDA-0.02x
Interest coverage38.82x
Owners' fund to total sources76.51%
Debt to assets4.28%
Cash flow
Cash from Operating Activity (latest year)Rs 3 Cr
Cash from Investing Activity (latest year)Rs -14 Cr
Cash from Financing Activity (latest year)Rs 5 Cr
Net Cash Flow (latest year)Rs -6 Cr
Free cash flow (latest year)Rs -13 Cr
FCFE (approx.: FCF + change in debt)Rs -12 Cr
Cash from ops / profit, 5 years0.30x
Sales to cash flow18.00x
Statement figures
Net sales (TTM)Rs 75 Cr
Net sales (latest year)Rs 57 Cr
Sales (latest quarter)Rs 24 Cr
Operating profit excl. other income (latest year)Rs 29 Cr
Operating profit (latest quarter)Rs 21 Cr
Other income (TTM)Rs 4 Cr
EBITDA (TTM)Rs 53 Cr
PBDT (TTM)Rs 51 Cr
Profit before tax (TTM)Rs 48 Cr
Tax (latest year)Rs 7 Cr
Net profit (TTM)Rs 36 Cr
Net profit (latest year)Rs 22 Cr
Net profit (latest quarter)Rs 15 Cr
Depreciation (TTM)Rs 4 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 16 Cr
Total expenditure (latest year)Rs 28 Cr
Total income (latest year)Rs 61 Cr
Share capitalRs 44 Cr
ReservesRs 46 Cr
Shareholders' fundsRs 90 Cr
Total assetsRs 117 Cr
Net blockRs 22 Cr
Capital work in progressRs 12 Cr
InvestmentsRs 0 Cr
ReceivablesRs 23 Cr
InventoryRs 14 Cr
Other liabilitiesRs 23 Cr
Shares outstanding (crore)43.79
Ownership
Promoter holding51.16% (+0.21 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 75.1 is at the 69th percentile of its own 9.2-year range
(median 53.0, low 11.6, high 328.4).
P/B 30.12 is at the 96th percentile (median 1.47).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | SHUKRAPHAR | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +10.8% | -2.8% | +13.6 pts |
| 1 month | +39.1% | -6.8% | +45.9 pts |
| 3 years | +1488.7% | +14.2% | +1474.5 pts |
| 5 years | +16163.2% | +27.9% | +16135.3 pts |
Red flags
F-score 7 of 8| explain | Weak cash conversion Cash from operations was 12% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 16% of total assets in 2026 |
| explain | Receivables outrunning sales Receivables grew 162% vs sales +74% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹24 Cr +380.0% vs Jun 2025.
Net profit ₹15 Cr +1400.0%.
Against our estimate for Jun 2026: sales +200.0%, profit +603.1% beat. Our estimate for Sep 2026: sales Rs 10 Cr, profit Rs 4 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-21 | Dividend - Re 0.01 Per Share |
| Date | Type | What it says |
|---|---|---|
| 2026-09-29 | Shareholder meeting | Voting results. |
| 2026-09-28 | Board meeting outcome | Outcome of Board Meeting held on September 28, 2026. |
| 2026-09-18 | Record Date | Record date for the purpose of Dividend is 21-Sep-2026. |
| 2026-09-05 | Shareholder meeting | Notice of Annual General Meeting to be held on September 28, 2026 |
| 2026-09-03 | General Updates | General Updates |
| 2026-09-03 | General Updates | General Updates |
| 2026-09-02 | Board meeting outcome | Outcome of Board Meeting held on September 02, 2026. |
| 2026-08-27 | Shareholder meeting | Notice of Postal Ballot |
| 2026-08-22 | Board meeting outcome | Outcome of Board Meeting held on August 22, 2026. |
| 2026-08-17 | General Updates | General Updates |
| 2026-08-14 | General Updates | General Updates |
| 2026-08-14 | General Updates | General Updates |
| 2026-08-14 | General Updates | General Updates |
| 2026-08-14 | General Updates | General Updates |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 25perc in previous 1 month
Quick answers
What is the market cap of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) has a market capitalisation of Rs 2,659 Cr. at the 2026-10-01 close.
What is the P/E ratio of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd trades at a P/E of 73.8 on trailing twelve-month profit, at the 2026-10-01 close.
What were Shukra Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Shukra Pharmaceuticals Ltd sales was Rs 24 Cr (+380.0% vs Jun 2025) and net profit was Rs 15 Cr.
What is the 52-week high and low of Shukra Pharmaceuticals Ltd?
The 52-week high is Rs 63.36 and the 52-week low is Rs 40.06.